19
Jubilant Generics, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is RISPERIDONE, with a corresponding application number 90839.
Regulatory Information RX
With a dosage strength 4MG
Dosage Form Route TABLET, ORALLY DISINTEGRATING; ORAL
Reference Listed Drug No
Approved since 2011-11-04
Therapeutic Equivalence (TE) Code AB
18
Jubilant Generics, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is RISPERIDONE, with a corresponding application number 90839.
Regulatory Information RX
With a dosage strength 2MG
Dosage Form Route TABLET, ORALLY DISINTEGRATING; ORAL
Reference Listed Drug No
Approved since 2011-11-04
Therapeutic Equivalence (TE) Code AB
17
Jubilant Generics, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is RISPERIDONE, with a corresponding application number 90839.
Regulatory Information RX
With a dosage strength 0.5MG
Dosage Form Route TABLET, ORALLY DISINTEGRATING; ORAL
Reference Listed Drug No
Approved since 2011-11-04
Therapeutic Equivalence (TE) Code AB
16
Jubilant Generics, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is RISPERIDONE, with a corresponding application number 90839.
Regulatory Information RX
With a dosage strength 3MG
Dosage Form Route TABLET, ORALLY DISINTEGRATING; ORAL
Reference Listed Drug No
Approved since 2011-11-04
Therapeutic Equivalence (TE) Code AB
15
Jubilant Generics, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is RISPERIDONE, with a corresponding application number 90839.
Regulatory Information RX
With a dosage strength 1MG
Dosage Form Route TABLET, ORALLY DISINTEGRATING; ORAL
Reference Listed Drug No
Approved since 2011-11-04
Therapeutic Equivalence (TE) Code AB